Background Obesity is on course to overtake being underweight as a global disease
burden. Obesity alters antibacterial pharmacokinetics (PK) and pharmacodynamics (PD) …

What is known and objective Obesity is a significant burden on the healthcare system in the
U nited S tates, and determining the appropriate antimicrobial dosing regimen in morbidly …

The prevalence of obesity has increased considerably in the last few decades.
Pathophysiological changes in obese patients lead to pharmacokinetic (PK) and …

Physiologic alterations seen in obesity commonly impact the pharmacokinetics (PK) and
pharmacodynamics (PD) of antibiotics and may result in suboptimal dosing in this …

Drug dosing in obese patients continues to be challenging due to a lack of high‐quality
evidence to guide dosing recommendations. We first published guidance for antibiotic …

Highlights•A singular approach to antimicrobial dose selection in obese patients is not
feasible.•Total body weight based dosing risks over exposure and toxicity in obese …

Individuals with obesity are at increased risk of developing infectious diseases. Timely
administration of an effective dose of an antimicrobial agent is paramount to safeguard …

No matter how depressing it sounds, obesity is here to stay! Despite a significant increase in
the awareness of causes of obesity, extensive media campaign from public health …

Obesity and its related comorbidities can negatively influence the outcomes of certain
infectious diseases. Specific dosing recommendations are often lacking in the product label …

As obesity continues to increase in prevalence throughout the world, it becomes important to
explore the effects that obesity has on antimicrobial disposition. Physiologic changes in …